Research programme: solid tumour therapies - ViRexx

Drug Profile

Research programme: solid tumour therapies - ViRexx

Alternative Names: Occlusin; Occlusin 500 Artificial Embolization Device; Occlusin 500 Device; Tactin

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ViRexx Medical Corp
  • Class Albumins
  • Mechanism of Action Platelet aggregation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Liver cancer; Solid tumours; Uterine leiomyoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-cancer in Canada (Intrahepatic)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Canada (IV-injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Uterine-leiomyoma in Canada (Intrauterine)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top